Linezolid for the Treatment of Multidrug‐Resistant, Gram‐Positive Infections: Experience from a Compassionate‐Use Program
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Birmingham et al 202 reported cure in 17 of 22 courses of therapy (77%) for E faecium IE.”
Citations
Cites
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088
Linezolid resistance in a clinical isolate of Staphylococcus aureus
Tsiodras, S., Gold, H. S., Sakoulas, G., Eliopoulos, G. M., Wennersten, C., Venkataraman, L., Moellering, R. C., & Ferraro, M. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05410-1 · Cited by 1,033
Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
Gonzales, R. D., Schreckenberger, P. C., Graham, M. B., Kelkar, S., DenBesten, K., & Quinn, J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04376-2 · Cited by 542
Stevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Self-citationIn vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Vancomycin Resistance in Staphylococci
Srinivasan, A., Dick, J. D., & Perl, T. M. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.3.430-438.2002 · Cited by 285
Thrombocytopenia Associated with Linezolid Therapy
Attassi, K., Hershberger, E., Alam, R., & Zervos, M. J. (2002) · Clinical Infectious Diseases · doi:10.1086/338403 · Cited by 259
Slatter, J. G., Stalker, D. J., Feenstra, K. L., Welshman, I. R., BRUSS, J. B., Sams, J. P., Johnson, M. G., Sanders, P., Hauer, M. J., Fagerness, P. E., et al. (2001) · PubMed · Cited by 248
Nosocomial Spread of Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium
Herrero, I. A., Issa, N. C., & Patel, R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200203143461121 · Cited by 241
Michel, M., & Gutmann, L. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11192-2 · Cited by 220
Linezolid and Reversible Myelosuppression
Green, S. L. (2001) · JAMA · doi:10.1001/jama.285.10.1291 · Cited by 187
Hematologic Effects of Antimicrobials: Focus on the Oxazolidinone Linezolid
Kuter, D. J., & Tillotson, G. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.11.1010.34517 · Cited by 134
Linezolid absolute bioavailability and the effect of food on oral bioavailability
Welshman, I. R., Sisson, T. L., Jungbluth, G. L., Stalker, D. J., & Hopkins, N. K. (2001) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.255 · Cited by 133
Li, Z., Willke, R. J., Pinto, L. A., Rittenhouse, B., Rybak, M. J., Pleil, A. M., Crouch, C. W., Hafkin, B., & Glick, H. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.3.263.34198 · Cited by 130
Jones, R. N., Johnson, D. M., & Erwin, M. E. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.720 · Cited by 128
Kaatz, G. W., & Seo, S. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.799 · Cited by 112
Serotonin Syndrome and Linezolid
Wigen, C. L., & Goetz, M. B. (2002) · Clinical Infectious Diseases · doi:10.1086/340710 · Cited by 110
Oxidation of the Novel Oxazolidinone Antibiotic Linezolid in Human Liver Microsomes
Wynalda, M. A., Hauer, M. J., & Wienkers, L. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15179-3 · Cited by 99
Hendershot, P. E., Antal, E. J., Welshman, I. R., Batts, D. H., & Hopkins, N. K. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010302 · Cited by 86
Self-citationLinezolid and Serotonin Syndrome
Lavery, S., Ravi, H., McDaniel, W. W., & Pushkin, Y. R. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.5.432 · Cited by 81
Ashtekar, D. R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., & RITTEL, W. (1991) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(91)90002-w · Cited by 74
Linezolid‐Induced Anemia and Thrombocytopenia
Waldrep, T. W., & Skiest, D. J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.1.109.33504 · Cited by 65
Linezolid: MAOI Activity and Potential Drug Interactions
Hammerness, P. G., Parada, H. J., & Abrams, A. N. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.3.248-a · Cited by 15
Research works printed but not linked: 8
- 2002, MMWR Morb Mortal Wkly Rep, 51, 565
- Stalker DJ, 1997, DC: American Society for Microbiology, 23
- Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days [abstract A115]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:23.
- Wynalda MA, 2000, Drug Metab Dispos, 28, 1014
- Slatter JG, 2001, Drug Metab Dispos, 29, 1136
- Dresser LD, Birmingham MC, Karchmer AW, Rayner CR, Falvin SM, Schentag JJ. Results of treating infective endocarditis with linezolid [abstract 2239]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
- Zurenko GE, Todd WM, Hafkin B, etal Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1997:118.
- Forrest A, Rayner CR, Meagher AK, Birmingham MC, Schentag JJ. Pharmacostatistical modelling of hematologic effects of linezolid (L) in seriously-ill patients (pts) [abstract 283]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000:5.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Lew, D. P., & Waldvogel, F. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16727-5 · Cited by 1,883
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Moise-Broder, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443130-00005 · Cited by 757
Self-citation
Metadata
- Authors
- Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Kalamazoo Public Library (US)
- Corresponding author
- Schentag, Jerome J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 36
- Issue
- 2
- Pages
- 159-168
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153039659
- Semantic Scholar
- 884899ebe7caae27908d4715f8dc57cf1db6c0c1
- Cited by
- 428
- References
- 25
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 7 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 17 · 2017: 14 · 2016: 13 · 2015: 21 · 2014: 19 · 2013: 19 · 2012: 13
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- linezolid, compassionate use program, vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, bacteremia, endocarditis, osteomyelitis, complicated skin and skin structure infections, intra-abdominal infection, clinical cure, adverse events, drug tolerability
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Anti-Infective Agents, Drug Interactions, Female, Humans, Male, Middle Aged, Treatment Outcome, Gram-Positive Bacterial Infections, Drug Resistance, Multiple, Oxazolidinones, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.